For HIV-1–negative, at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1. See full Indication.

HPTN 083
See the safety profile of APRETUDE compared with a daily oral PrEP (TDF/FTC) in cisgender men and transgender women who have sex with men and have evidence of high-risk behavior for HIV-1 infection.

HPTN 084
Review safety data for APRETUDE as compared with a daily oral PrEP (TDF/FTC) in cisgender women at risk of acquiring HIV-1.
HPTN=HIV Prevention Trials Network; PrEP=pre-exposure prophylaxis; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.
CBTWCNT230017